GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Return-on-Tangible-Equity

PharmaRoth Labs (PharmaRoth Labs) Return-on-Tangible-Equity : 0.00% (As of Mar. 2011)


View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PharmaRoth Labs's annualized net income for the quarter that ended in Mar. 2011 was $-0.40 Mil. PharmaRoth Labs's average shareholder tangible equity for the quarter that ended in Mar. 2011 was $-0.31 Mil. Therefore, PharmaRoth Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2011 was N/A%.

The historical rank and industry rank for PharmaRoth Labs's Return-on-Tangible-Equity or its related term are showing as below:

ROTH's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -47.52
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

PharmaRoth Labs Return-on-Tangible-Equity Historical Data

The historical data trend for PharmaRoth Labs's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Return-on-Tangible-Equity Chart

PharmaRoth Labs Annual Data
Trend Jun08 Jun09 Jun10
Return-on-Tangible-Equity
- - -

PharmaRoth Labs Quarterly Data
Mar07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaRoth Labs's Return-on-Tangible-Equity

For the Biotechnology subindustry, PharmaRoth Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaRoth Labs's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaRoth Labs's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PharmaRoth Labs's Return-on-Tangible-Equity falls into.



PharmaRoth Labs Return-on-Tangible-Equity Calculation

PharmaRoth Labs's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2010 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2010 )  (A: Jun. 2009 )(A: Jun. 2010 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2010 )  (A: Jun. 2009 )(A: Jun. 2010 )
=-0.27/( (-0.023+-0.292 )/ 2 )
=-0.27/-0.1575
=N/A %

PharmaRoth Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2011 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2011 )  (Q: Dec. 2010 )(Q: Mar. 2011 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2011 )  (Q: Dec. 2010 )(Q: Mar. 2011 )
=-0.404/( (-0.321+-0.295)/ 2 )
=-0.404/-0.308
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2011) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


PharmaRoth Labs  (GREY:ROTH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


PharmaRoth Labs Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaRoth Labs (PharmaRoth Labs) Business Description

Traded in Other Exchanges
N/A
Address
8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117
PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines